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Pharmacology of Antiparkinsonian Agents 
Robert P. Soltis 1 
College of Pharmacy and Health Sciences, Drake University, Des Moines I A 50311 
PROLOGUE 
The following is a summary of a two hour class on the basic 
pharmacology of antiparkinsonian agents. It is presented to 
fourth-year pharmacy students in pharmacotherapeutics 
III, a course structured using team-taught modules. Faculty 
from the Department of Pharmacy Sciences provide in-
struction on the basic pharmacology of therapeutic agents 
and faculty from the Department of Pharmacy Practice 
follow up with a discussion of the therapeutic applications of 
these agents. This course is lecture-based with opportunities 
for in-class discussion. 
One week prior to the lecture sequence on the basic 
pharmacology of antiparkinsonian drugs, students are pro-
vided a handout that includes the reading assignment (1), 
learning objectives and a topic outline. The topic outline 
contains the chemical structures of the agents to be dis-
cussed as well as the figures, patient scenarios and study 
questions appearing in this manuscript. During each 50-
minute period, material is presented as a lecture tied to 
patient scenarios. The scenarios are presented in class im-
mediately after covering the pharmacological concepts to 
which they apply. Students are asked to discuss in small 
groups potential solutions to the scenarios and to offer their 
answers to the rest of the class on a volunteer basis. The 
study questions are geared for preparing for exams and are 
not discussed in class unless students request. At the end of 
these two lectures, a homework problem is assigned that 
introduces the 6-hydroxydopamine rat model of Parkinson’s 
disease. The following week, a live demonstration related to 
the homework is presented in class with a short discussion 
afterwards. 
The objectives of these classes focus on understanding 
the pharmacological mechanisms of drug therapy for 
Parkinson’s disease and using this information to predict or 
solve drug-related problems. Specifically, the student should 
be able to: (i) describe the symptoms and neuropathology 
associated with Parkinson’s disease; (ii) discuss how current 
drug therapy and the different mechanisms of action are 
useful in the treatment of Parkinson’s disease; (iii) under-
stand how the course and the severity of the disease can 
affect drug therapy; and (iv) predict potential side effects 
and drug interactions and suggest ways to alleviate these 
problems based on pharmacological and pharmacokinetic 
concepts. 
PARKINSON’S DISEASE 
Parkinson’s disease is a disorder of the central nervous 
system that is characterized by three cardinal features: (i) 
bradykinesia (slowness of movement); (ii) muscular rigid-
ity; and (iii) resting tremor that stops upon voluntary move-
ment. Other symptoms that may occur include stooped 
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Fig. 1. Neuronal projections from the motor cortex and substantia 
nigra to the striatum in normal (left) and parkinsonian patients 
(right). Minus signs (-) represent the inhibitory actions of dopamine 
(DA); plus signs represent the excitatory actions of acetylcholine 
(Ach) and glutamate (Glu) in the striatum. 
posture with a characteristic shuffling gait, sialorrhea and 
dementia during the later stages of the disease (2-5). 
The disease is characterized by a selective loss or degen-
eration of the nigrostriatal pathway. This pathway consists 
of neurons that project from the substantia nigra to the 
striatum and use dopamine as the neurotransmitter (Figure 
1). Acetylcholine and glutamate are also present as neu-
rotransmitters in the striatum but are unaffected by the 
disease. As a consequence, there is an imbalance between 
the inhibitory actions of dopamine and the excitatory ac-
tions of acetylcholine and glutamate in the striatum. All of 
the major symptoms seen in Parkinson’s disease appear to 
be attributed to this imbalance. Interestingly, the symptoms 
of Parkinson’s disease do not present until 70-80 percent of 
the dopamine neurons in the nigrostriatal tract are lost. This 
suggests that a large redundancy of the nigrostriatal path-
way or compensatory mechanisms in other pathways exist 
that correct for the loss of nigrostriatal pathway until a 
critical point is reached (4, 6). 
Typically the symptoms of Parkinson’s disease do not 
occur until after age 55 and affect approximately one per-
cent of the elderly population worldwide. If the disease is 
left untreated, patients become rigid and akinetic. As the 
disease progresses, Parkinsonian patients lose the ability to 
care for themselves and suffer from complications associ-
ated with immobility such as pulmonary embolism and 
pneumonia (5). 
The cause of Parkinson’s disease is unknown. Several 
theories have been suggested including a genetic link, toxins 
and oxidative stress. It appears that in the vast majority of 
cases, the disease is not genetically determined. While there 
are well documented cases of families with a high incidence 
of Parkinson’s disease, these cases constitute only a small 
fraction of Parkinsonian patients (3-5,7,8). 
 American Journal of Pharmaceutical Education   Vol. 61, Summer 1997 179 
Fig. 2. Relative amounts of dopamine (DA) and acetylcholine (Ach) in 
the striatum of normal (left) and parkinsonian patients (right). 
Addition of a dopamine agonist or an anticholinergic agent attempts 
to restore the proper balance between DA and Ach in the 
Parkinsonian patient. 
Normal adults experience approximately one percent 
loss of striatal dopamine per year. Given that Parkinsonian 
symptoms do not appear until later in life and only until after 
70 percent or more of striatal dopamine is depleted, it is 
possible that Parkinson’s disease results from two processes; 
a specific disease-related insult that does not reduce the 
dopamine content to symptomatic levels combined with the 
gradual loss of neurons during normal aging. This may 
explain why Parkinson’s disease is a progressive disorder of 
late onset. Thus, the progression of symptoms may not 
necessarily be the result of an active disease process but 
rather may be the effects of aging superimposed on the 
initial insult. That is, the neuronal destruction may have 
occurred early in life but the symptoms do not appear until 
later in life when additional neurons are lost during normal 
aging (4). 
Certain drug therapies can also produce Parkinsonian-
like symptoms. Most notable are dopamine receptor an-
tagonists used in the treatment of schizophrenia (haloperidol, 
chlorpromazine) and emesis (metoclopramide, 
prochlorperazine). The antihypertensive agent reserpine 
can also produce Parkinsonian-like symptoms because of its 
ability to deplete neuronal stores of dopamine. By prevent-
ing the uptake of dopamine into storage vesicles, reserpine 
makes dopamine available for destruction by monoamine 
oxidase (MAO) present within the nerve terminal. The 
Parkinsonian-like symptoms associated with these drugs are 
reversible and subside upon discontinuing the drug or de-
creasing the dose. 
PHARMACOTHERAPY 
Symptoms associated with Parkinson’s disease result from 
an imbalance between dopamine (deficiency) and acetyl-
choline (excess). Current drug therapy focuses on restoring 
the balance between these two neurotransmitters. In theory, 
any drug that can penetrate the blood brain barrier and 
produce an effect that results in the activation of dopamine 
receptors or in the blockade of muscarinic receptors should 
be of value in treating Parkinson’s disease. The diagram in 
Figure 2 depicts the relative amounts of dopamine and 
acetylcholine in normal and Parkinsonian patients. Addi-
tion of either a dopamine agonist or an anticholinergic 
(muscarinic antagonist) in a Parkinsonian patient helps to 
restore the proper balance between these two neurotrans-
mitters. Bear in mind that the current drug therapies treat 
only the symptoms of the disease; they do not cure or appear 
to alter the long term course of the underlying disease. 
 
Fig. 3. Synthetic and metabolic pathways of dopamine. 
L-DOPA 
Levo-dihydroxyphenylalanine (L-DOPA) is the amino 
acid precursor to dopamine. It is absorbed through the 
blood brain barrier by an active transport system. Once into 
the brain, L-DOPA is taken up into the nerve terminal and 
decarboxylated by aromatic L-amino acid decarboxylase 
(AAADC) to form dopamine (Figures 3 and 4). Appar-
ently, there are enough surviving neurons for the synthesis 
and release of dopamine to occur and produce a therapeutic 
effect. Dopamine itself cannot be used because it does not 
pass through the blood brain barrier; it is too highly ionized 
and is not a substrate for the active transport system. Of all 
the L-DOPA administered, about one percent enters the 
brain while the remainder is decarboxylated in the periph-
ery. Therefore, 99 percent of the L-DOPA that is adminis-
tered is wasted in the sense that it is metabolized before it 
can get to the site of action in the brain (4). 
Study Question 
Based on information in Figures 3 and 4, suggest 
other drugs or mechanisms which may be useful in 
the treatment of Parkinson’s disease. 
L-DOPA is rapidly absorbed from the small intestine by 
an active transport system for aromatic amino acids. Peak 
plasma concentration occurs in 30 to 90 minutes following 
oral administration. Plasma half-life is relatively short; 1 to 3 
hours. However, the brain half-life is longer because L-
DOPA is taken up by neurons (protecting it from metabo-
lism) and stored. 
One important food-drug interaction with regard to L-
DOPA involves dietary protein. Ingested proteins are hydro-
lyzed to amino acids in the gastrointestinal tract prior to their 
absorption. These amino acids will compete with L-DOPA
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Fig. 4. Synapse depicting the synthesis, storage, release, post-synap-
tic receptor interaction, metabolism and reuptake of dopamine. 
for absorption carrier sites in the small intestine and slow the 
movement of L-DOPA into the blood stream. Pharmacoki-
netic data substantiate that the administration of L-DOPA 
with food delays absorption and reduces peak plasma concen-
trations. Dietary amino acids can also compete with L-DOPA 
for active transport sites at the blood brain barrier. Conse-
quently, the therapeutic effects of intravenously adminis-
tered L-DOPA can also be influenced by diet (5). 
The side effect profile of L-DOPA can be categorized 
into early and late occurring events. The most common side 
effects that occur early in therapy are nausea and vomiting. 
Hypotension and cardiac arrhythmias are also possible in 
the initial days of therapy but are not as common. These 
initial side effects are peripheral in origin (i.e., do not involve 
the CNS) and are mediated by dopamine. L-DOPA itself 
has few, if any, pharmacological actions. Therefore, these 
side effects can be reduced or eliminated by the addition of a 
peripheral inhibitor of AAADC, the enzyme that coverts L-
DOPA to dopamine (see below). Alternatively, adminis-
tration of vitamin supplements containing vitamin B6 (pyri-
doxine), a cofactor for AAADC, will increase the periph-
eral conversion of L-DOPA to dopamine resulting in more 
side effects and a reduced therapeutic effect. 
Side effects that occur later in therapy (2-4 months) 
include nightmares, hallucinations, psychosis and abnor-
mal, involuntary movements such as dyskinesia or dystonia. 
These delayed side effects are of central origin and occur 
following administration of relatively high doses. Conse-
quently, these side effects cannot be alleviated by the addi-
tion of a peripheral inhibitor of AAADC but instead are 
reversed or controlled by reducing the dose. This can be 
problematic given that reducing the dose may result in loss 
of some of the beneficial effects of therapy (9). 
During the first few years of L-DOPA therapy, the 
patient usually has smooth, day-long control of the symp-
toms. However, as the disease progresses, problems begin to 
arise. During the course of the day, the patient may experi-
ence “peak-dose dyskinesia” which are involuntary move-
ments occurring at the time of peak plasma levels - too much 
dopamine. Later in the day, the patient may experience 
“end-of-dose hypokinesia”; Parkinsonian symptoms occur-
ring at the time of low or subtherapeutic plasma concentra-
tion. These changes are referred to as the “on-off phenom 
enon” or the “wearing off phenomenon”. In some instances, 
the “on” portion may occur with the rising plasma concen-
trations rather than the peak concentrations and the “off” 
portion occur with the falling concentrations rather than the 
troughs. As a result, the on-off in some patients may occur 
within relatively short periods of time. In either case, the 
motor fluctuations tend to follow the kinetics of L-DOPA 
and, therefore, are fairly predictable (3,5). 
The theory of why this form of on-off occurs later in 
therapy is based on the progressive loss of dopamine neu-
rons. In newly diagnosed patients (i.e., mild Parkinsonism), 
there are enough neurons still present to adequately synthe-
size and store enough dopamine to offset the rise and fall of 
L-DOPA plasma concentrations. As the disease progresses, 
more neurons die and post synaptic receptors adapt by 
upregulating or becoming supersensitive. As a result, with 
fewer neurons, the synthetic and storage capabilities of 
dopamine are lessened and the sensitivity of the dopamine 
receptors is heightened. Now, the range of therapeutic 
plasma concentrations of L-DOPA becomes much more 
narrow. The peak plasma concentration represents too much 
dopamine and produces dyskinesias. The trough concentra-
tion represents not enough dopamine and results in 
Parkinsonian symptoms. Dietary factors and dosing regi-
mens become very important at this point. Strategies to 
reduce the frequency of the on-off phenomenon include low 
protein diet, continuous gastric infusion, sustained release 
formulations or giving smaller doses more frequently(2). 
Another type of on-off phenomenon has been described 
in which the fluctuations between mobility and immobility 
are random. That is, the changes do not appear to follow the 
kinetics of L-DOPA. The mechanism for this form of on-off 
is unclear but may involve the interaction of several factors 
including pharmacokinetic and pharmacodynamic changes 
associated with chronic, high-dose L-DOPA therapy. 
Whereas it is possible to treat the predictable fluctuations 
with changes in dosage, frequency and route of administra-
tion, the random on-off phenomenon is difficult, if not 
impossible, to treat(2, 5). 
Carbidopa 
As stated above, only one percent of an orally adminis-
tered dose of L-DOPA reaches the CNS because of decar-
boxylation in the periphery. The conversion of L-DOPA to 
dopamine in the periphery is responsible for some of the side 
effects associated with L-DOPA therapy. These problems 
can be alleviated by administration of carbidopa, a periph-
eral inhibitor of AAADC. Carbidopa inhibits AAADC by 
forming a covalent inhibitory complex with the enzyme’s 
cofactor pyridoxal phosphate, a form of vitamin B6 (10). 
Carbidopa does not penetrate the blood brain barrier be-
cause it is too highly ionized and is not a substrate for the 
active transport system. Therefore, it stays in the periphery. If 
the drug were to get into the CNS, it would negate L-
DOPA therapy because L-DOPA would not be converted 
to the active form dopamine (4). 
The addition of carbidopa to L-DOPA therapy offers a 
number of advantages including: (i) reduction in the dose of 
L-DOPA by 75 percent; (ii) reduction of all of the peripheral 
side effects (but not the central side effects); and (iii) no 
need to avoid vitamin B6 supplements. The L-DOPA/ 
carbidopa combination product is Sinemet®. Rarely will L-
DOPA therapy be used without carbidopa or some other 
inhibitor of AAADC. 
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L-DOPA is the most effective drug therapy for 
Parkinson’s disease and is considered the mainstay of treat-
ment. Early in the course of the disease, improvement in the 
three cardinal features of the disease is nearly complete 
along with improvement in handwriting and speech. There 
is also an increase in the patient’s sense of well being and 
ability to function in society secondary to improvement of 
symptoms. However, as the disease progresses, L-DOPA 
therapy tends to fail and additional drugs may be added to 
the regimen. The drugs discussed below are used primarily 
as adjuncts. They may be used alone in the early stages of 
Parkinson’s disease but their major role is as add-on therapy 
in later stages of the disease (3, 7). 
Patient Scenario 
DK is a 65 year old female with advanced Parkinson’s 
Disease. Her husband cares for her full-time and 
confides in you that ever since the physician in-
creased her dose of Sinemet®, she has been acting 
goofy; she talks to people who do not exist and she 
wants to stay in at night because she claims the night 
air makes her hair fall out. Explain why DK is acting 
“goofy”. Are there any changes in or additions to 
DK’s drug regimen that may alleviate these symp-
toms? 
Bromocriptine (Parlodel®) and Pergolide (Permax®) 
Bromocriptine and pergolide are dopamine receptor 
agonists. Theoretically, these drugs should offer some ad-
vantages over L-DOPA because they do not require active 
transport mechanisms for absorption from the GI tract or 
for passage through the blood brain barrier. Furthermore, 
these drugs do not rely upon functional dopamine nerve 
terminals for synthesis and release of the active agent. The 
side effect profile of these two agents is similar to L-DOPA; 
nausea, vomiting, hypotension but with a potentially higher 
incidence of hallucinations than L-DOPA. In addition, 
bromocriptine has the potential to produce severe orthos-
tatic hypotension following the first dose(5). 
In clinical practice, bromocriptine and pergolide are no 
more effective than L-DOPA. The putative selectivity of 
bromocriptine for the D2 dopamine receptor subtype does 
not appear to offer any therapeutic advantage. (The dopam-
ine receptor family is covered in detail in lectures on schizo-
phrenia where the pharmacology of dopamine receptor 
subtypes is better defined with antagonists.) The role in 
therapy of these two agents is relegated to use as adjuncts to 
L-DOPA therapy during periods of excessive on-off or 
when higher doses of L-DOPA are required but cannot be 
tolerated(2,5,7). 
Amantadine (Symmatrel®) 
The mechanism of action of amantadine is not clear. It 
appears to cause release and inhibit reuptake of dopamine 
(Figure 4). It may have anticholinergic activity as well which 
can contribute to its antiparkinsonian effects (Figures 1 and 
2). Side effects tend to be relatively mild and include dizzi-
ness, nausea and vomiting (3,5). 
The use of amantadine is limited to mild cases of 
Parkinson’s disease or as an adjunct to L-DOPA. A draw-
back to its use is its apparent loss of efficacy after 4-8 weeks 
of therapy. Interestingly, amantadine was introduced ini-
tially (and is still used) for the prevention and treatment of 
influenza A. Its potential use as an antiparkinsonian agent
was discovered by accident when the Parkinsonian symp-
toms of patients being treated for the flu improved during 
the course of amantadine treatment (4). 
Benztropine (Cogentin®) and Trihexyphenidyl (Artane®) 
Benztropine and trihexyphenidyl are two examples of 
muscarinic cholinergic receptor antagonists. Their mecha-
nism of action with regard to the treatment of Parkinson’s 
disease is to block the relative excess of acetylcholine in the 
striatum to restore the balance between acetylcholine and 
dopamine (Figures 1 and 2). These drugs are helpful in 
reducing tremor but not the rigidity or slowness of move-
ment. Side effects of these agents are predictable and are 
based on blockade of the parasympathetic nervous system. 
In addition, the sedation and mental confusion often associ-
ated with anticholinergics tend to be more pronounced in 
the elderly and, therefore, an important concern in many 
Parkinsonian patients. 
Prior to the use of L-DOPA, anticholinergics were the 
most effective drugs for the treatment of Parkinson’s dis-
ease. Today, anticholinergics are used as adjuncts to L-
DOPA therapy. They are used in patients with mild forms of 
Parkinson’s disease, or in patients who cannot tolerate or 
who do not respond to L-DOPA therapy. All anticholin-
ergics used in the treatment of Parkinson’s disease are 
equally effective. However, be aware that an individual 
patient may tolerate or respond to one preparation better 
than another (2,5,7). 
Selegiline (Eldepryl®) 
Selegiline is a relatively selective inhibitor of monoam-
ine oxidase B (MAO-B). MAO-B is the predominate form 
of monoamine oxidase in the striatum and is responsible for 
the majority of oxidative metabolism of dopamine in this 
region. Consequently, inhibition of this enzyme should re-
sult in more dopamine being available for release (Figures 3 
and 4). Selegiline is metabolized to amphetamine and 
methamphetamine which may also play a role in producing 
an antiparkinsonian effect by increasing the release of dopam-
ine (3). 
Selegiline is also being looked at as a possible 
neuroprotective agent. One theory suggests that the neu-
ronal loss associated with Parkinson’s disease results from 
the formation of oxygen free radicals from MAO-mediated 
deamination of dopamine. Selegiline has also been shown to 
prevent the Parkinsonian syndrome associated with admin-
istration of the toxin N-methy1-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) by inhibiting the MAO-B me-
diated formation of the toxic metabolite 1-methyl-4-
phenylpyridium (MPP+). If oxygen free radicals or an MPTP-
like toxin is responsible for Parkinson’s disease, then 
selegiline may be useful in slowing or preventing the pro-
gression of this disease (7). Recent studies, however, have 
failed to demonstrate with any definitive proof that selegiline 
is neuroprotective with regard to idiopathic Parkinson’s 
disease (3-5,7). 
Selegiline alone is well tolerated; insomnia and anxiety 
are the most commonly cited side effects. At recommended 
doses, selegiline is not associated with the potential for 
eliciting a hypertensive crisis as seen with the non-selective 
MAO inhibitors used in the treatment of depression. At 
doses of 10 mg/day or less, selegiline does not inhibit the 
metabolism of peripheral catecholamines or exogenous in-
direct acting sympathomimetics such as tyramine found in
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certain drinks and foods (wine, cheese). However, at doses 
above 10 mg/day, selegiline loses its selectivity for MAO-B 
and may produce this reaction. In addition, selegiline, like 
the non-selective MAO inhibitors, has been observed to 
produce hyperthermia and convulsions following adminis-
tration of the opioid analgesic meperidine (Demerol®)(5). 
In early stages of Parkinson’s disease, selegiline may be 
used alone. More commonly, it is used in combination with 
L-DOPA because it allows for a lowering of the dose of L-
DOPA as well as increasing the time between doses. It is of 
limited value, however, in patients with advanced Parkinson’s 
disease (5). 
Patient Scenario 
Sy Kosis is a 72 year old male diagnosed with 
Parkinson’s disease six years ago. He is fairly well 
controlled with current therapy but complains of 
some “good days and some bad days.” His daughter 
is concerned about him taking diphenhydramine (25 
mg) for his allergies. Will the diphenhydramine be 
beneficial, harmful or have no effect with regard to 
the symptoms of Parkinson’s disease in this patient? 
Are there any other concerns about the use of 
diphenhydramine in this patient? 
POTENTIAL NEW THERAPIES 
Glutamate is the major excitatory neurotransmitter in the 
CNS. Recent research has focused on the glutamate recep-
tor as a site of drug action in the treatment of various 
diseases including Parkinson’s disease, schizophrenia, epi-
lepsy and stroke. Given that glutamate is one of the excitatory 
neurotransmitters in the striatum, it has been suggested that 
blockade of glutamate transmission may be beneficial in the 
treatment of Parkinson’s disease (6, 11). For example, in 
some animal models of Parkinson’s disease, glutamate an-
tagonists can relieve some of the signs and symptoms of the 
disease. The dose of L-DOPA needed to alleviate these 
signs can be dramatically reduced by combining L-DOPA 
with a glutamate antagonist. MPTP-induced Parkinsonism 
can be prevented by pretreating with glutamate antago-
nists(6-8,ll). Lamotrigine, an anticonvulsant that inhibits 
the release of glutamate, may be helpful in improving some 
of the clinical signs and symptoms of Parkinson’s disease (12). 
Study Question 
Use a diagram similar to the one in Figure 2 to show 
the imbalance that exists between dopamine and 
glutamate and describe the mechanism of drugs that 
may restore this imbalance. 
The information below is provided in a handout at the 
end of the lecture series on Parkinson’s disease. The stu-
dents are asked to consider the study problem and be ready 
to discuss their answers following a live demonstration of 
the model in class the following week. 
RAT MODEL OF PARKINSON’S DISEASE 
The nigrostriatal tract is a major pathway in the basal 
ganglia that controls posture and movement. The cell bodies 
of these neurons lie in the substantia nigra and the axons 
project to the striatum where the nerve terminals release 
dopamine. Dopamine activates postsynaptic dopamine re-
ceptors located in the striatum. Loss or destruction of the 
nigrostriatal neurons appears to be the cause of movement
problems in Parkinson’s disease. Note that there are two 
nigrostriatal tracts in the brain (both humans and rats); one 
on the left side and one on the right side. 
In the rat model of Parkinson’s disease, the neurotoxin 
6-hydroxydopamine (6-OHDA) is injected into the right 
side of the brain of a normal rat. The 6-OHDA is taken up 
into nerve terminals that have reuptake mechanisms for 
dopamine. Once inside the cell, 6-OHDA kills the entire 
neuron - cell body, axon and nerve terminal. Cell death 
occurs within 24^48 hours. At this point, the dopamine 
receptors in the right striatum are receiving no input; the 
nerves that release dopamine are absent. The striatum (post 
synaptic cell) adapts by making more dopamine receptors 
(upregulating or supersensitization). The left side of the 
brain did not receive the toxin and the receptors and neu-
rons remain unchanged (normal). There is now an imbal-
ance of dopamine receptors between the left striatum and 
the right striatum. 
If a full dopamine agonist is administered systemically 
(PO, IV or SC) to a normal rat, the rat’s response will be an 
increase in motor activity — mostly sniffing, gnawing and 
random movement in its cage. If a full dopamine agonist is 
administered systemically to a rat previously injected with 6-
OHDA into the right side of the brain, the rat’s motor 
behavior will be a constant circling to the left. 
1. Draw and label the neuronal connections of the left and 
right nigrostriatal pathways of a rat receiving an injec-
tion of 6-OHDA into the right side of the brain. 
2. Which side of the brain is receiving greater stimulation 
of dopamine receptors when a full dopamine agonist is 
administered systemically? Why? 
3. If the rat circles to the left when a full dopamine agonist 
is administered, which direction will it turn if amphet-
amine is given systemically to the same rat? Why? 
(Amphetamine causes the release of dopamine from 
nerve terminals.) 
4. What direction will the rat turn if a dopamine reuptake 
inhibitor is administered systemically? 
CONCLUSION 
The intent of the above information is to provide a clear and 
organized overview of the drug therapy for Parkinson’s 
disease with the opportunity to reinforce the material through 
discussions and problem solving exercises. The student 
evaluations for this portion of the course have been over-
whelming positive. Students indicate that the patient sce-
narios are helpful in understanding the connection between 
the pharmacology of the drugs and their therapeutic appli-
cations. The scenarios also provide the students a break 
from the didactic lecture and give them a chance to reflect on 
the material and ask other related questions. The demon-
stration of the Parkinsonian rat model has also been viewed 
very favorably. The pharmacotherapeutics sequence is taught 
without a laboratory and, therefore, this demonstration 
(and others occurring later in the sequence) offers another 
useful method of reinforcing material. 
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